Shares of Incyte Corp. rallied 4.83% to $70.81 Thursday, on what proved to be an all-around positive trading session for the ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D organization to ...

A high-level overview of Alnylam Pharmaceuticals, Inc. (ALNY) stock. View (ALNY) real-time stock price, chart, news, analysis, analyst reviews and more.

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $339.39, a high estimate of $500.00, and a low estimate of $268.00.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the polyneuropathy manifestations of ATTR amyloidosis and hereditary transthyretin ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9, 2025, that AMVUTTRA® (vutrisiran) has been approved by the European ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

Alnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic porphyria (AHP). A recently released patient storytelling initiative by the ...

Thirty-three life sciences companies are slated to receive $29.9 million in tax incentives for creating 1,519 new industry ...